DiaMedica Therapeutics Enhances ReMEDy2 Trial for Acute Ischemic Stroke Treatment

DiaMedica Therapeutics Enhances Trial Protocol for Acute Ischemic Stroke

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company specializing in innovative therapies for severe ischemic diseases, announces significant enhancements to its ReMEDy2 trial protocol targeting Acute Ischemic Stroke (AIS). Following in-depth discussions with trial investigators and stroke experts, the company adjusts the trial's parameters to expand the patient population and improve the study's overall efficacy. These changes aim to include patients who do not respond to standard thrombolytic treatments, such as tissue plasminogen activator (tPA) or tenecteplase (TNK).

The new protocol increases the interim analysis sample size from 144 to 200 subjects, a strategic move designed to refine the statistical analysis and potentially reduce the total number of participants required. By implementing these modifications, DiaMedica seeks to shorten the trial timeline and minimize associated costs. The company's previous ReMEDy1 Phase 2 trial revealed that patients who had received tPA prior to enrollment exhibited the highest response rates. This insight supports the decision to include non-responders—patients who continue to experience neurological deficits after thrombolytic therapy—in the ReMEDy2 trial, thereby enhancing the trial's primary outcome measures.

DiaMedica submitted these protocol changes to the U.S. Food and Drug Administration (FDA) on August 30, 2024, and has yet to receive comments from the agency, allowing the company to proceed with implementation. These strategic alterations signal DiaMedica's commitment to optimizing its therapeutic interventions for severe ischemic conditions, positioning the company for potential success in a critical area of unmet medical need.

In addition to the trial enhancements, DiaMedica is set to hold a conference call on November 14, 2024, at 8:00 AM Eastern Time to further discuss its business developments and financial results for the quarter ending September 30, 2024. This call will provide stakeholders with additional insights into the company’s progress and strategic direction.

As the clinical landscape for treating AIS evolves, DiaMedica's focus on addressing the needs of non-responding patients sets a precedent for innovative approaches in the biopharmaceutical industry. The company's proactive adjustments to the ReMEDy2 trial not only promise to enhance patient outcomes but also reflect a broader commitment to advancing treatment options for severe ischemic diseases.